Published in Clin Cancer Res on March 01, 2011
Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov (2012) 1.96
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 1.23
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med (2011) 1.18
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
Quantitative Imaging in Cancer Clinical Trials. Clin Cancer Res (2016) 1.08
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging (2012) 1.02
State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology (2014) 0.97
The clinical significance and management of lesion motion due to respiration during PET/CT scanning. Cancer Imaging (2011) 0.95
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One (2013) 0.90
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PLoS One (2014) 0.86
New strategy for monitoring targeted therapy: molecular imaging. Int J Nanomedicine (2013) 0.85
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun (2016) 0.84
FLT PET-CT in evaluation of treatment response. Indian J Nucl Med (2014) 0.84
Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis (2014) 0.82
Role of FDG PET/CT in assessing response to targeted therapy in metastatic lung cancers: Morphological versus metabolic criteria. Indian J Nucl Med (2015) 0.82
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer (2016) 0.81
FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol (2014) 0.80
In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography. Oncotarget (2015) 0.79
TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. Eur J Nucl Med Mol Imaging (2016) 0.79
Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat (2011) 0.78
Comparison of the diagnostic performance of (18)F-fluorothymidine versus (18)F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis. Mol Clin Oncol (2014) 0.78
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. Eur J Nucl Med Mol Imaging (2017) 0.77
A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. Cancer Med (2014) 0.77
Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer. J Biomed Biotechnol (2012) 0.76
Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Transl Oncol (2016) 0.75
Multimodality molecular imaging of the lung. Clin Transl Imaging (2014) 0.75
Early (18)F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. EJNMMI Res (2016) 0.75
(18)F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Cancer Imaging (2017) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell (2007) 5.84
Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell (2010) 5.73
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
A navigator for human genome epidemiology. Nat Genet (2008) 5.07
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res (2005) 4.94
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Development and validation of a CGH microarray for clinical cytogenetic diagnosis. Genet Med (2005) 3.39
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res (2010) 3.20
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics (2015) 2.93
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol (2015) 2.80
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A (2004) 2.66
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res (2005) 2.65
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol (2013) 2.55
Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell (2012) 2.54
Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use? J Nucl Med (2011) 2.52
Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science (2013) 2.49
Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells. Nat Cell Biol (2006) 2.39
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am J Epidemiol (2006) 2.34
Epithelial polarity and tubulogenesis in vitro. Trends Cell Biol (2003) 2.31
Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell (2011) 2.29
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res (2012) 2.25
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther (2009) 2.16
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2003) 2.14
Cell-polarity dynamics controls the mechanism of lumen formation in epithelial morphogenesis. Curr Biol (2008) 2.13
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.12
Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol (2015) 2.12
Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res (2009) 2.05
Suicide in lung cancer: who is at risk? Chest (2013) 2.02
Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res (2011) 2.01
Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol (2009) 1.89
The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. Clin J Am Soc Nephrol (2013) 1.87
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics (2011) 1.79
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol (2006) 1.73
Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog (2012) 1.71
Cancer GAMAdb: database of cancer genetic associations from meta-analyses and genome-wide association studies. Eur J Hum Genet (2011) 1.69
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med (2010) 1.67
Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging (2006) 1.67
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 1.66
Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med (2002) 1.65
Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res (2012) 1.63
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med (2002) 1.62
Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography. Int J Radiat Oncol Biol Phys (2008) 1.60
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol (2003) 1.59
Morphological and biochemical analysis of Rac1 in three-dimensional epithelial cell cultures. Methods Enzymol (2006) 1.59
Age structure changes and extraordinary lifespan in wild medfly populations. Aging Cell (2008) 1.57
Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer (2011) 1.57
Conditional mutagenesis of the murine serum response factor gene blocks cardiogenesis and the transcription of downstream gene targets. J Biol Chem (2005) 1.56
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res (2012) 1.55
ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther (2012) 1.55
Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist (2005) 1.53
Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma (2003) 1.52
Detection of pulmonary emboli with 99mTc-labeled anti-D-dimer (DI-80B3)Fab' fragments (ThromboView). Am J Respir Crit Care Med (2011) 1.51
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol (2008) 1.48
Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg (2002) 1.47
Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging (2004) 1.47
Nudel functions in membrane traffic mainly through association with Lis1 and cytoplasmic dynein. J Cell Biol (2004) 1.47
Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell Res (2013) 1.46
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck (2005) 1.45
Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med (2006) 1.43
Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET. J Nucl Med (2012) 1.43
Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol (2008) 1.42
Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med (2010) 1.42
Polarity proteins PAR6 and aPKC regulate cell death through GSK-3beta in 3D epithelial morphogenesis. J Cell Sci (2007) 1.42
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood (2004) 1.39
Identification of direct serum-response factor gene targets during Me2SO-induced P19 cardiac cell differentiation. J Biol Chem (2005) 1.38
Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet (2012) 1.38
Horizon scanning for new genomic tests. Genet Med (2011) 1.36
Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing, China, compared with whites in the United States: the Beijing osteoarthritis study. Arthritis Rheum (2002) 1.36
Crizotinib and testing for ALK. J Natl Compr Canc Netw (2011) 1.35
Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis (2004) 1.35
Genetic epidemiology with a capital E, ten years after. Genet Epidemiol (2011) 1.34
Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii. J Exp Med (2008) 1.33